17.45
-0.37(-2.08%)
Currency In USD
Address
238 Main Street
Cambridge, MA 02142
United States of America
Phone
857 327 8775
Website
Sector
Healthcare
Industry
Biotechnology
Employees
393
First IPO Date
February 06, 2020
| Name | Title | Pay | Year Born |
| Mr. John M. Evans M.B.A. | Chief Executive Officer & Director | 1.23M | 1978 |
| Mr. Sravan Kumar Emany | Chief Financial Officer | 617,074 | 1978 |
| Dr. Christine P. Bellon J.D., Ph.D. | Senior Vice President, Chief Legal Officer & Corporate Secretary | 744,950 | 1966 |
| Dr. Amy Simon M.D. | Chief Medical Officer | 779,170 | 1964 |
| Dr. Giuseppe Ciaramella Ph.D. | President | 1.04M | 1969 |
| Dr. Manmohan Singh Ph.D. | Chief Technology Officer | 0 | N/A |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder | 0 | N/A |
| Dr. Feng Zhang Ph.D. | Co-Founder | 0 | N/A |
| Dr. David R. Liu Ph.D. | Co-Founder | 0 | N/A |
| Dr. Gopi Shanker Ph.D. | Chief Scientific Officer | 0 | N/A |
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.